Venlafaxina

Efexor, Zarelis e altri

Bibliografia - Quali fonti bibliografiche per Venlafaxina?

1. Abdelmawla A.H. et al., Br. J. Clin. Pharmacol., 1999, 48, 345.


2. Akkaya C. et al., Hum. Psychopharmacol., 2006, 21 (5), 337.


3. Altamura A.C. et al., Int. Clin. Psychopharmacol., 1999, 14 (4), 239.


4. Can. J. Psychiatry, 2003, 48 (2), letter.


5. Combes A. et al., Ann. Int. Med., 2001, 134, 166.


6. Cunningham L.A.,et al., J. Clin. Psychopharmacol., 1994, 14, 99.


7. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.


8. Davidson J.R. et al., J. Clin. Psychiatry, 1999, 60 (8), 528.


9. De Abajo F.J. et al., BMJ, 1999, 319, 1106.


10. Drent M. et al., Am. J. Respir. Crit. Care Med., 2003, 167, 958, (abstract).


11. Einarson A. et al., Am. J. Psychiatry, 2001, 158, 1728.


12. Evans M.L. et al., Obstet. Gynecol., 2005, 105, 161.


13. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.


14. Fabre L.F., Putman III H.P., Curr. Ther. Res., 1987, 42, 901.


15. Ferguson J. et al., Neuropsychopharmacology, 1994, 10 (2), 117.


16. Fisher A., Davis M., Ann. Pharmacother., 2002, 36, 67.


17. Fleisch M.C. et al., Eur. Respir. J., 2000, 15, 205.


18. Garcia Muret M.P. et al., 58th Ann. Meeting Am. Acc. Dermatol., 2000, 10 marzo.


19. Gelemberg A.J. et al., JAMA, 2000, 283 (23), 3082.


20. Gründer G. et al., Pharmacopsych., 1993, 26, 155.


21. Hannan N. et al., J. Psychopharmacol., 21 (2), 2007, 161.


22. Kaplan E.M. et al., Clin. Ther., 2002, 24, 1194.


23. Kelsey J.E. et al., Psychopharmacol. Bull., 1995, 31 (4), 767.


24. Lancet, 2009, 373, 746.


25. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.


26. Lee Y. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 1139.


27. Loprinzi C.L. et al., Lancet, 2000, 356, 2059.


28. Loprinzi C.L. et al., J. Clin. Oncol., 2006, 24 (9), 1409.


29. Mason P.J. et al., Medicine, 2000, 79, 201.


30. Markovitz P.J., Wagner S.C., Psychopharmacol. Bull., 1995, 31 (4), 773.


31. McCue R.E., Joseph M., Am. J. Psychiatry, 2001, 158, 2088.


32. Meijer W.E. et al., Arch. Intern. Med., 2004, 164, 2367.


33. Mills K.C., Critical Care Clinics, 1997, 13, 763.


34. Montgomery S.A. et al., J. Psychiatr. Res., 2002, 36 (4), 209.


35. Montgomery S.A. et al., J. Clin. Psychiatry, 2006, 67 (5), 771.


36. Moses-Kolko E.L. et al., JAMA, 2005, 293, 2372.


37. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.


38. Muth E.A. et al., Biochem. Pharmacol., 1986, 35, 4493.


39. Muth E.A. et al., Drug Dev. Res., 1991, 23, 191.


40. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.


41. Papp et al. Psychopharmacol. Bull., 1998, 34 (2), 207.


42. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.


43. Perry N, Postgraduate Medical Journal, 2000, 76, 254.


44. Prescr. Int. 1998, 7 (36), 112.


45. Prescr. Int., 2004, 13, 57.


46. Preskorn S.H. et al., Eur. J. Psychiat., 1997, 12 (Suppl. 4), 285S.


47. Prior F.H. et al., Med. J. Austr., 2002, 176, 240.


48. Saletu B. et al., Br. J. Clin. Pharm., 1992, 33, 589.


49. Schweizer E. et al., J. Clin. Psychopharmacol., 1991, 11, 233.


50. Silverstone P.H., Ravindra A., J. Clin. Psychiatry, 1999, 60 (1), 22.


51. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.


52. Troy S.M. et al., J. Clin. Pharmacol., 1995, 35 (4), 410.


53. van Walraven C. et al., BMJ, 2001, 323, 655.


54. Vanokoski, Sommarberg L., TABU, 2004, 6, 53.


55. Whyte I.M. et al., Quarterly J. Med., 2003, 96, 369.